Reykajvik (IFN) deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended March 31, 2006. A conference call to discuss the quarter's results and recent operating highlights will be webcast live tomorrow, Tuesday, May 2, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer time (details below).
Revenue for the first quarter 2006 was $10.1 million, compared to $9.5 million for the first quarter 2005. At March 31, 2006, the company had $15.9 million in deferred revenue, which will be recognized over future reporting periods.
Net loss for the first quarter 2006 was $20.3 million, compared to $16.9 million for the first quarter last year. The principal component of this increase is higher research and development expense related to clinical trials and preclinical development work in the company's lead drug development programs. Reported results for the first quarter of 2006 also reflect the adoption of Financial Accounting Standards Board Statement of Financial Accounting Standards No. 123 (revised 2004), Share-based Payment, (FAS 123R), resulting in a charge of $0.9 million, or $0.02 per basic and diluted share, for share-based compensation. Basic and diluted net loss per share was $0.37 for the first quarter 2006, compared to $0.32 for year ago period. At the close of the first quarter 2006, the company had approximately 55.5 million shares outstanding.
At March 31, 2006, the company had $140.3 million in cash and investments, compared to $155.6 million at December 31, 2005.
Research and development expense for proprietary programs was $14.9 million for the first quarter of this year, compared to $8.3 million for the first quarter 2005. This increase is the result principally of costs associated with the advancement of the company's lead drug discovery and development programs.
Selling, general and administrative expenses for the first quarter 2006 were $5.3 million, compared to $4.2 million for the same period last year. The principal factor in this increase was share-based compensation expense resulting from the adoption of FAS 123R.
"deCODE is advancing the development of new drugs for a broad and growing range of major diseases, and I expect the coming weeks and months to be an exciting period in our growth as a biopharmaceutical company. By midyear we expect to begin enrollment in our Phase III trial for DG031; initiate a Phase II program for DG041 for peripheral artery disease (PAD); complete the analysis of the data from our asthma trial; and be well on the way towards an IND for DG051, our follow-on compound in heart attack. I believe our results for the past quarter demonstrate the fundamental advantage of our capabilities in human genetics: enabling us to discover and develop new drugs in major therapeutic areas, and to do so in a cost-effective manner," said Kari Stefansson, CEO of deCODE.
Recent highlights include:
Drug Discovery and Development
* Heart attack: DG031. deCODE is preparing for the launch of the
Phase III outcome trial for DG031, its lead developmental compound
for the prevention of heart attack, and expects to begin enrollment by
the end of the second quarter of this year. To date we have identified
and are evaluating more than 100 study sites and have taken delivery
of 3.5 million tablets for the trial. The trial is being designed
under a Special Protocol Assessment with the US Food and Drug
Administration (FDA), and deCODE expects to begin recruitment shortly
after the SPA process is completed. We aim to maximize the sensitivity
and likelihood of success of the Phase III study by focusing it on the
group at highest risk through the pathway targeted by the compound:
African-American heart patients who carry the HapK variant of the
gene encoding the leukotriene A4 hydrolase (LTA4H). Our gene discovery
work has shown that while HapK modestly increases the risk of heart
attack in people of European descent, African Americans with the HapK
variant are at a more than a 250% increased risk of the disease. The
gene variants deCODE has linked to heart attack appear to confer
increased risk by raising the production of leukotriene B4 (LTB4),
a potent mediator of inflammation expressed in atherosclerotic
plaques. In Phase II trials completed last year, DG031 was shown
to be well-tolerated and to reduce the production of LTB4 in a
* Heart attack: DG051. We are conducting advanced preclinical work on a
follow on compound for the prevention of heart attack. This compound
targets leukotriene A4 hydrolase (LTA4H), which acts further down the
same pathway modulated by FLAP, the target of DG031. In preclinical
studies this compound, DG051, has been shown be a potent inhibitor of
LTB4 production; is orally bioavailable; should allow for once-a-day
oral dosing; and appears to have minimal potential for drug-drug
interaction. We are on track to file an IND for DG051 by mid-year
* PAD: DG041. In February we concluded the Phase I clinical program for
DG041, our compound for the treatment of peripheral artery disease
(PAD), and are on track to begin a Phase II program by the end of the
second quarter of this year.
* Asthma. We have concluded our Phase II clinical trial in asthma under
a drug development alliance with the company whose compound we are
testing. The study is examining safety and tolerability, as well as
improvement in lung function and reduction in airway inflammation. We
expect to finish the analysis of the data from this trial by the
middle of this year.
* Pain: DG061. Exploiting our drug discovery work in PAD, deCODE is
bringing forward a lead preclinical candidate, DG061, to meet the need
for alternatives to the selective COX-2 inhibitors and other NSAIDs
for the treatment of pain. Preclinical studies of DG061 demonstrate
that it is orally active and efficacious in an animal model for pain.
deCODE expects to file an IND on DG061 in 2006.
* Type 2 Diabetes. In January, deCODE reported the discovery of the most
significant genetic risk factor for type 2 diabetes (T2D) found to
date. More than one third of individuals in the populations studied
carry one copy of the at-risk variant and are at an approximately 45%
greater risk of the disease than are controls; 7% carry two copies and
are at a 141% greater risk. The company is employing the discovery in
its diagnostic and drug discovery programs in T2D.
deCODE genetics (Nasdaq: DCGN) is a global leader in applying human genetics to develop drugs for common diseases. Our population approach has enabled us to discover and target key biological pathways involved in conditions ranging from heart attack to cancer. We are turning these discoveries into new medicine to better treat and prevent many of the biggest challenges to public health. deCODE is delivering on the promise of the new genetics.(SM) Visit us on the web at http://www.decode.com.
Conference Call Information
A conference call, during which deCODE President and CEO Kari Stefansson and CFO Lance Thibault will discuss first quarter financial results and recent operating highlights, will be webcast tomorrow, Tuesday, May 2, at 8:00am EDT/12 noon GMT/1pm British Summer Time. The webcast can be accessed via the Investors section of deCODE's website, http://www.decode.com, or through http://www.earnings.com. A replay of the call will be available on these websites for at least one week following the call. A digitized telephone replay of the call can be accessed for the week following the call by dialing 1 800 475 6701 from the US, or +1 320 365 3844 from outside the US. The access code is 827175.
Condensed Consolidated Statements of Operations
For the three months
ended March 31,
In thousands, except share
and per share amounts
Revenue $ 10,133 $ 9,523
Research and development -
proprietary programs 14,890 8,275
Cost of revenue, including
collaborative programs 10,477 9,140
Selling, general and administrative 5,267 4,158
Total operating expense 30,634 21,573
Operating loss (20,501) (12,050)
Interest income 1,712 1,120
Interest expense (1,716) (2,389)
Other non-operating income and (expense), net 232 (3,617)
Net loss $ (20,273) $ (16,936)
Basic and diluted net loss per share: $ (0.37) $ (0.32)
Shares used in computing basic and
diluted net loss per share 54,601,111 53,648,977
Condensed Consolidated Balance Sheet Data
March 31, December 31,
In thousands, (unaudited)
Cash, cash equivalents, and investments $ 140,296 $ 155,554
Total assets 198,662 206,758
Total liabilities 220,471 216,095
Total shareholders' equity (deficit) (21,809) (9,337)
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Joy Bessenger Edward Farmer
+354 570 1900 +354 570 1900
+1 (212) 481 3891 +1 212 343 2819
SOURCE deCODE genetics
/CONTACT: Joy Bessenger, +354-570-1900, +1-212-481-3891, email@example.com, or Edward Farmer, +354-570-1900, +1-212-343-2819, firstname.lastname@example.org, both of deCODE genetics
/Web site: http://www.decode.com
Icelandic Financial News (IFN) is available on Factiva, a joint venture between Reuters and Dow Jones Newswires, FT.COM, LexisNexis, Comtex, Gale and Thomson via the Nordic Business Report.